{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:43Z","timestamp":1790717143430,"version":"4.1.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:p>This case report describes a 78-year old woman with a stage IIA <jats:italic>BRAF<\/jats:italic> wild-type melanoma on the left leg who experienced a grade 2 vitiligo, a marked skin thickening, and painful swelling of the limbs.<\/jats:p>","DOI":"10.1001\/jamadermatol.2022.5146","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T16:33:26Z","timestamp":1669826006000},"page":"112","source":"Crossref","is-referenced-by-count":9,"title":["Tocilizumab for Corticosteroid-Refractory Immune Checkpoint Inhibitor\u2013Induced Generalized Morphea"],"prefix":"10.1001","volume":"159","author":[{"given":"Manon","family":"Blaise","sequence":"first","affiliation":[{"name":"Dermatology Department, Centre Hospitalier Universitaire de Nice, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cardot-Leccia","sequence":"additional","affiliation":[{"name":"Department of Pathology, Centre Hospitalier Universitaire de Nice, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seitz-Polski","sequence":"additional","affiliation":[{"name":"Immunology Department, Centre Hospitalier Universitaire de Nice, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Picard-Gauci","sequence":"additional","affiliation":[{"name":"Dermatology Department, Centre Hospitalier Universitaire de Nice, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Bertold","sequence":"additional","affiliation":[{"name":"Dermatology Department, Centre Hospitalier Universitaire de Nice, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"Dermatology Department, Centre Hospitalier Universitaire de Nice, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Montaudi\u00e9","sequence":"additional","affiliation":[{"name":"Dermatology Department, Centre Hospitalier Universitaire de Nice, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"dlo220019r1","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features.","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"dlo220019r2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jaad.2021.06.849","article-title":"Late-onset adverse events of anti-PD1 therapy in melanoma patients: an observational study from MELBASE, a nationwide prospective cohort.","volume":"86","author":"Carlet","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"dlo220019r3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1001\/jamadermatol.2018.5040","article-title":"A case of pansclerotic morphea treated with tocilizumab.","volume":"155","author":"Zhang","year":"2019","journal-title":"JAMA Dermatol"},{"key":"dlo220019r4","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2147\/DDDT","article-title":"Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.","volume":"10","author":"Sakkas","year":"2016","journal-title":"Drug Des Dev Ther"},{"issue":"157","key":"dlo220019r5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"dlo220019r6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2798842\/jamadermatology_blaise_2022_lo_220019_1673370607.24271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T16:02:47Z","timestamp":1674057767000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2798842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.5146","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,1]]}}}